We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

55 hedge funds and large institutions have $379M invested in Inozyme Pharma in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 11

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3.12% more ownership

Funds ownership: 78.57% → 81.69% (+3.1%)

2% more funds holding

Funds holding: 54 → 55 (+1)

0% more capital invested

Capital invested by funds: $379M → $379M (+$398K)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
55
Holders Change
+1
Holders Change %
+1.85%
% of All Funds
0.97%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
6
Increased
21
Reduced
11
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$18M
2
BlackRock
BlackRock
New York
+$5.1M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.26M
4
CCM
CAAS Capital Management
New York
+$3.92M
5
Millennium Management
Millennium Management
New York
+$3.29M

Top Sellers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
-$13.2M
2
O
OrbiMed
New York
-$8.26M
3
YU
Yale University
Connecticut
-$2.34M
4
CA
CHI Advisors
New York
-$1.5M
5
Citadel Advisors
Citadel Advisors
Florida
-$268K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$486K +$108K +4,897 +25%
Goldman Sachs
27
Goldman Sachs
New York
$471K +$65.1K +2,951 +14%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$462K +$43.9K +1,988 +9%
N
29
Nuveen
North Carolina
$422K – – –
JP Morgan Chase
30
JP Morgan Chase
New York
$422K +$386K +17,488 +456%
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$359K +$129K +5,845 +48%
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$338K +$377K +17,091 New
OMC
33
Overbrook Management Corp
New York
$331K – – –
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$285K -$28.9K -1,311 -8%
New York State Common Retirement Fund
35
New York State Common Retirement Fund
New York
$244K +$108K +4,900 +66%
Bank of America
36
Bank of America
North Carolina
$231K +$253K +11,479 +6,413%
State of Wisconsin Investment Board
37
State of Wisconsin Investment Board
Wisconsin
$226K – – –
LCM
38
Laurion Capital Management
New York
$203K – – –
PNC Financial Services Group
39
PNC Financial Services Group
Pennsylvania
$180K – – –
Ensign Peak Advisors
40
Ensign Peak Advisors
Utah
$158K – – –
Deutsche Bank
41
Deutsche Bank
Germany
$157K +$39.4K +1,787 +29%
DekaBank Deutsche Girozentrale
42
DekaBank Deutsche Girozentrale
Germany
$128K – – –
CLOS
43
Compagnie Lombard Odier SCmA
Switzerland
$50K – – –
SO
44
STRS Ohio
Ohio
$39K – – –
Wells Fargo
45
Wells Fargo
California
$34K -$176K -7,993 -82%
Citigroup
46
Citigroup
New York
$25K -$21.9K -991 -44%
Legal & General Group
47
Legal & General Group
United Kingdom
$24K +$7.13K +323 +36%
TRCT
48
Tower Research Capital (TRC)
New York
$23K -$5.32K -241 -17%
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$22K +$19K +861 +329%
UBS Group
50
UBS Group
Switzerland
$20K +$22.1K +1,002 New
1
2
3

INZY Hedge Fund Activity: Q1 2021 in Review

55 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q1 2021, worth a combined $379M — up 0.11% from $379M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new INZY positions and 5 closed out — a net gain of 1 holder — while 21 added to existing stakes and 11 trimmed.

The largest buyer was Deerfield Management, adding an estimated $18M. The largest seller was Novo Holdings A/S, cutting an estimated $13.2M.

  • 55 institutional investors held Inozyme Pharma (INZY) as of Q1 2021, up from 54 in Q4 2020.
  • Funds reported $379M of Inozyme Pharma stock for Q1 2021, up 0.11% quarter-over-quarter.
  • 6 funds opened new Inozyme Pharma positions in Q1 2021 and 5 closed out, a net change of +1 holder.
  • The largest Inozyme Pharma buyer in Q1 2021 was Deerfield Management, an estimated $18M added.
  • The largest Inozyme Pharma seller in Q1 2021 was Novo Holdings A/S, an estimated $13.2M sold.

Based on aggregated 13F filings for Q1 2021.